Patrys Limited ( (AU:PAB) ) has provided an update.
Patrys Limited announced the retirement of Mr. Michael Stork, a long-serving Non-Executive Director and major shareholder, effective March 31, 2025. Mr. Stork has been instrumental in the company’s development since its ASX listing in 2007, contributing significantly to its governance and strategic planning. His departure marks a significant transition for Patrys, which continues to advance its innovative deoxymab platform, aiming to transform cancer treatment and address unmet medical needs in inflammatory diseases.
More about Patrys Limited
Patrys Limited, based in Melbourne, Australia, is a therapeutic antibody development company focusing on its deoxymab platform. These cell-penetrating antibodies are designed to treat various cancers by targeting DNA fragments released from dying cells, making them versatile for different cancer types. Patrys is also exploring the potential of deoxymabs in addressing NETosis-driven inflammatory diseases, with several patents granted worldwide for their innovative approaches.
Technical Sentiment Signal: Buy
Current Market Cap: €3.71M
For an in-depth examination of PAB stock, go to TipRanks’ Stock Analysis page.